News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rockwell Medical (RMTI) Announces Triferic™ Iron Replacement Clinical Data To Be Presented At 14th Asian Pacific Congress Of Nephrology May 14-17, 2014 In Tokyo, Japan



4/29/2014 9:24:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WIXOM, Mich., April 29, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that an oral presentation and poster for Trifericâ„¢ will be presented at the 14th Asian Pacific Congress of Nephrology May 14-17, 2014 in Tokyo, Japan. Trifericâ„¢ is the Company's late-stage investigational iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES